Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding(Memorial Sloan Kettering Cancer Center), Sebastián Mondaca, Madappa N. Kundranda(The University of Texas MD Anderson Cancer Center), Laëtitia Dahan, Ari David Baron, Marine Jary, Filippo de Braud(University of Milan), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando), Muhammad Shaalan Beg, Elisabetta Fenocchio(Candiolo Cancer Institute), J. Adeva Alfonso, Hui‐Chuan Sun(Fudan University), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Lequn Bao(Hubei Cancer Hospital), Roopinder Gillmore, Daneng Li(City Of Hope National Medical Center), Jieer Ying(Zhejiang Cancer Hospital), Laura Layos, Omkar Marathe, Sara Lonardi(Istituto Oncologico Veneto), Milind Javle(The University of Texas MD Anderson Cancer Center), Massimo Aglietta(Verizon (United States)), Antonio Cubillo Gracián(Hospital Universitario HM Sanchinarro), Do‐Youn Oh(Seoul National University Hospital), Jung Hun Kang(Gyeongsang National University Hospital), Emerson Y. Chen(Oregon Health & Science University), Lisa Boyken(Zymeworks (Canada)), Harpreet Wasan(Hammersmith Hospital), Eric X. Chen(Princess Margaret Cancer Centre), Hye Jin Choi(Yonsei University), Jean‐Philippe Metges(Centre Hospitalier Régional Universitaire de Brest), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), John Bridgewater(University College London Hospitals NHS Foundation Trust), Jiafang Ma(BeiGene (China)), Shubham Pant(The University of Texas MD Anderson Cancer Center), Michel Ducreux(Université Paris-Saclay), Dong Uk Kim(Pusan National University Hospital), Olumide Gbolohon, Jin Won Kim(Seoul National University Bundang Hospital), Jia Fan(Nanjing Tech University), Ying Cheng(First Affiliated Hospital of Xi'an Jiaotong University), Yuanyuan Bao(BeiGene (China)), Feng Xie(Qingdao University), Paula Carrasco Aguirre, Heung-Moon Chang(Asan Medical Center), Gentry George King, Yixing Jiang, Tingbo Liang(Zhejiang University), Phillip M. Garfin(Zymeworks (Canada))
Cited by 243
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k